Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Sarepta Therapeutics (SRPT) NASDAQ

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 2,065,140
  • Shares Outstanding, K 54,590
  • Annual Sales, $ 1,250 K
  • Annual Income, $ -220,030 K
  • 36-Month Beta 1.90
  • Price/Sales N/A
  • Price/Book 4.90

Price Performance

See More
Period Period Low Period High Performance
1-Month
26.66 +34.96%
on 12/30/16
39.36 -8.59%
on 01/10/17
+4.86 (+15.62%)
since 12/16/16
3-Month
26.66 +34.96%
on 12/30/16
49.68 -27.58%
on 10/19/16
-13.90 (-27.87%)
since 10/18/16
52-Week
8.00 +349.75%
on 04/26/16
63.73 -43.54%
on 09/28/16
+21.70 (+151.96%)
since 01/15/16

Most Recent Stories

More News
Are Options Traders Betting on a Big Move in Sarepta Therapeutics (SRPT) Stock?

Investors in Sarepta Therapeutics (SRPT) need to pay close attention to the stock based on moves in the options market lately.

Sarepta Therapeutics Enters into Research Agreement and Option Agreement with Nationwide Children's Hospital for Microdystrophin Gene Therapy Program

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial stage developer of innovative RNA-targeted therapeutics, today announced it has entered a research and option agreement with Nationwide...

Sarepta Therapeutics Enters into License Agreement with Nationwide Children's Hospital for Galgt2 Gene Therapy Program

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial stage developer of innovative RNA-targeted therapeutics, today announced it has entered an exclusive license agreement with Nationwide...

Sarepta Therapeutics to Present Company Overview at the 2017 35th Annual J.P. Morgan Healthcare Conference

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial stage developer of innovative RNA-targeted therapeutics, today announced that it is scheduled to present at the 35th Annual J.P. Morgan...

How These Biotech Stocks are Faring? -- Celgene, Sarepta Therapeutics, MannKind and Amgen

Today, Stock-Callers.com navigates the Biotech arena to review the most recent performances of Celgene Corp. (NASDAQ: CELG), Sarepta Therapeutics Inc. (NASDAQ: SRPT), MannKind Corp. (NASDAQ: MNKD), and...

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage developer of innovative RNA-targeted therapeutics, granted equity awards on November 30, 2016, that were previously approved by...

3 Stocks to Add to Your Portfolio as Biotech M&A Hopes Rise

Will a Trump presidency trigger more M&A deals in the biotech sector?

Sarepta Therapeutics to Present Company Overview at the Credit Suisse 25th Annual Healthcare Conference

Sarepta Therapeutics (NASDAQ:SRPT), a commercial-stage developer of innovative RNA-targeted therapeutics, announced today that it is scheduled to present at the Credit Suisse 25th Annual...

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage developer of innovative RNA-targeted therapeutics, granted equity awards on October 31, 2016, that were previously approved by...

Sarepta Therapeutics (SRPT) Incurs Narrower Y/Y Loss in Q3

Sarepta Therapeutics, Inc. (SRPT) posted a loss of $1.15 per share in the third quarter of 2016, narrower than the year-ago loss of $1.25. The Zacks Consensus Estimate reported a loss of $1.35 per share....

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

See More

Business Summary

Sarepta Therapeutics, Inc. focuses on the discovery and development of RNA-based therapeutics for the treatment of rare and infectious diseases. The Company's diverse pipeline includes its lead program eteplirsen, for Duchenne muscular dystrophy. Sarepta Therapeutics, Inc., formerly known as AVI BioPharma,...

See More

Support & Resistance

2nd Resistance Point 37.36
1st Resistance Point 36.67
Last Price 35.98
1st Support Level 35.54
2nd Support Level 35.10

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.